Sumitomo Pharma (TSE:4506) Reports Strong First Quarter Earnings, Is The Discount Too Deep?

Sumitomo Pharma (TSE:4506) drew investor attention after reporting first quarter 2026 earnings, with sales of ¥129,495 million, net income of ¥16,997 million and basic earnings per share of ¥39.02 from continuing operations.

See our latest analysis for Sumitomo Pharma.

The earnings release comes after a mixed price pattern for Sumitomo Pharma, with the share price up 3.86% over one day and 5.86% over seven days, yet down 45.35% on a year to date basis. The 3 year total shareholder return of 162.80% contrasts with a 26.62% decline over five years, hinting at changing investor expectations over different timeframes.

If Sumitomo Pharma’s recent moves have your attention, it can also be useful to see what else is setting up in the market through 7 healthcare AI stocks

Sumitomo Pharma’s share price slide this year sits against a sizeable discount to both analyst targets and some fair value estimates. Is the market rightly cautious, or marking the stock down too far ahead of the numbers?

Most Popular Narrative: 32.8% Undervalued

On the latest figures, the most followed narrative values Sumitomo Pharma at ¥2,000 per share, compared with the last close at ¥1,345. That gap reflects a story built around its oncology and regenerative medicine pipeline as well as changes to earnings quality and margins.

Ambitious oncology and regenerative medicine programs such as enzomenib, nuvisertib and iPS cell therapies require accelerated clinical activity and shared development with partners. This may lift R&D outlays faster than product contributions, reducing near to medium term earnings leverage.

Read the complete narrative.

Analysts are incorporating expectations for faster top line expansion, thinner profit margins and a different profit multiple to reach that ¥2,000 value estimate. This raises the question of which assumptions matter most for Sumitomo Pharma, and how those moving parts fit together in the model.

Result: Value Estimate of ¥2,000 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still risks that could challenge this Sumitomo Pharma story, including pressure from future generic competition and one time gains fading faster than expected.

Find out about the key risks to this Sumitomo Pharma narrative.

Next Steps

With sentiment on Sumitomo Pharma split between concern and optimism, it can be useful to act promptly and test the assumptions yourself. You can review a balanced breakdown of the 3 key rewards and 3 important warning signs

Looking for more ideas beyond Sumitomo Pharma?

If Sumitomo Pharma has sharpened your focus, do not stop here. Use the Simply Wall St screener to line up your next set of opportunities before others do.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com